Purpura, Thrombocytopenic, Idiopathic Clinical Trial
Official title:
Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients
The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.
Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service
(FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of
intravenous immunoglobulin simplifies infusion, eliminates possible mistakes in the
reconstitution with water for injection and reduces space requirements in storage.
In addition to donor selection and screening, several procedures have been included in the
production process to improve viral safety.
In this clinical trial, the efficacy and safety of IVIG-L in patients with ITP will be
assessed and compared with data obtained from literature. IVIG-L will also be studied in
patients with hypogammaglobulinemia.The results from both studies will be used for an
application for marketing authorisation of IVIG-L in Finland and the Netherlands.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01356511 -
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
Completed |
NCT00540423 -
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00372892 -
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
Not yet recruiting |
NCT03252457 -
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
Phase 3 | |
Recruiting |
NCT05438875 -
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
|
Phase 3 | |
Completed |
NCT02281370 -
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT00547066 -
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
|
Phase 1/Phase 2 | |
Completed |
NCT00370331 -
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
|
Phase 3 | |
Completed |
NCT00828750 -
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00487968 -
Eltrombopag Taste Testing in Healthy Adult Volunteers
|
Phase 1 | |
Withdrawn |
NCT01317966 -
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT03443570 -
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
|
Phase 3 | |
Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
Completed |
NCT02201290 -
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00220727 -
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
|
Phase 2 | |
Completed |
NCT02334813 -
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
|
Phase 3 | |
Completed |
NCT02891109 -
Regulatory B Cells and Chronic Immune Thrombocytopenia
|
N/A | |
Completed |
NCT00706342 -
Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
Completed |
NCT03258866 -
The Study of Different Dose Rituximab in the Treatment of ITP
|
Phase 4 | |
Completed |
NCT01327872 -
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
|
Phase 1 |